Where Akkermansia Fits into the GLP-1 Ecosystem 1
CHUNDURI, Shriya, et al
Medical Eligibility Required Semaglutide and Tirzepatide cannot be prescribed to individuals with the following conditions: BMI under 27, eating disorders, Type 1 diabetes, gallbladder disease, substance abuse, recent bariatric surgery (within the past 6 months), pancreatitis or history of recurrent pancreatitis while taking a GLP-1 medication, medullary thyroid cancer, current pregnancy or breastfeeding, plans to become pregnant, diabetic retinopathy, multiple endocrine neoplasia type 2 (MEN2) or family history of MEN2, serious gastrointestinal disorders, or history of allergic reaction to Tirzepatide or Semaglutide
The authors hypothesized that H 2 O 2 formation in the mitochondria results in the inactivation of ATG4, promoting ATG8 lipidation, and thus, activation of autophagy